Category:BGT Paclitaxel Albumin Stabilized Nanoparticle Formulation(B2861)
From BiomedGT
BGT_Paclitaxel Albumin-Stabilized Nanoparticle Formulation(B2861)
Lexical
Concept Code: B2861
(O)
Preferred Name: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Coding Scheme: BGT (09.06a )
Synonym: Paclitaxel Albumin-Stabilized Nanoparticle Formulation (PT) (Source: NCI) / Abraxane (BR) (Source: NCI) / Albumin-Stabilized Nanoparticle Paclitaxel (SY) (Source: NCI) / nab paclitaxel (SY) (Source: NCI) / Nanoparticle Albumin-bound Paclitaxel (SY) (Source: NCI) / nab-paclitaxel (SY) (Source: NCI) / ABI 007 (CN) (Source: NCI) / ABI-007 (CN) (Source: NCI) / Nanoparticle Paclitaxel (SY) (Source: NCI)
Definition: A Cremophor ELP-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of Cremophor ELP and permits the administration of larger doses of this agent, which would be toxic in a Cremophor ELP-containing formulation due to Cremophor ELP's toxicity profile. Cremophor ELP is a nonionic solubilizer made by reacting castor oil with ethylene oxide in a molar ratio of 1:35, followed by a purification step. (NCI04) (Source: NCI)
URI: http://ncicb.nci.nih.gov/xml/owl/EVS/BiomedGT.owl#B2861
Properties
Accepted_Therapeutic_Use_For: Metastatic breast cancer
Semantic_Type: Pharmacologic Substance
NCI_META_CUI: CL035621
Def_Curator: NCI Drug Dictionary
In_Clinical_Trial_For: Metastatic Breast Cancer, Locally Advanced or Metastatic Solid Tumor
PDQ_Open_Trial_Search_ID: 38690
PDQ_Closed_Trial_Search_ID: 38690
Associations
Parent: Nanoparticle_targeted_Drug (primitive)
Parent: Paclitaxel_Preparation (primitive)
Form:LexWiki_BGT_Form
| BGT Accepted Therapeutic Use For(P302) | Metastatic breast cancer + |
| BGT Concept Type(P365) | O + |
| BGT Def Curator(P318) | NCI Drug Dictionary + |
| BGT In Clinical Trial For(P303) | Metastatic Breast Cancer, Locally Advanced or Metastatic Solid Tumor + |
| BGT NCI META CUI(P208) | CL035621 +info.pngNCI META CUI lookup |
| BGT PDQ Closed Trial Search ID(P330) | 38690 +info.pngPDQ Closed Trial Search |
| BGT PDQ Open Trial Search ID(P329) | 38690 +info.pngPDQ Open Trial Search |
| BGT Semantic Type(P106) | Pharmacologic Substance +info.pngSemantic Type lookup |
| BGT Synonym(P104) | Paclitaxel Albumin-Stabilized Nanoparticle Formulation +, Abraxane +, Albumin-Stabilized Nanoparticle Paclitaxel +, nab paclitaxel +, Nanoparticle Albumin-bound Paclitaxel +, nab-paclitaxel +, ABI 007 +, ABI-007 +, and Nanoparticle Paclitaxel + |
| DCTerms hasVersion(hasVersion) | BGT/Versions/09.06a + |
| Has default form | LexWiki BGT Form + |
| LexWiki Concept Code | B2861 + |
| LexWiki Definition | A Cremophor ELP-free, albumin-stabilized n … A Cremophor ELP-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of Cremophor ELP and permits the administration of larger doses of this agent, which would be toxic in a Cremophor ELP-containing formulation due to Cremophor ELP's toxicity profile. Cremophor ELP is a nonionic solubilizer made by reacting castor oil with ethylene oxide in a molar ratio of 1:35, followed by a purification step. (NCI04) (Source: NCI) a purification step. (NCI04) (Source: NCI) |
| LexWiki Preferred Name | Paclitaxel Albumin-Stabilized Nanoparticle Formulation + |
| LexWiki URI | http://ncicb.nci.nih.gov/xml/owl/EVS/BiomedGT.owl#B2861 + |
| SKOS inScheme(inScheme) | BGT + |
This category currently contains no articles or media.
